Cathie Wood has taken a lot of heat in recent years. She became one of Wall Street’s best-known fund managers during the pandemic rally, but her flagship ARK Innovation ETF (BATS:ARKK) fell sharply in 2022 and has trailed the market since. As of mid-November, ARKK is down about 4% in 2026, while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is up about 10%. Her trades keep drawing attention too, including her Nvidia (NASDAQ:NVDA) buying in August. Check out the full story here.
A closer look at ARK’s portfolio tells a different story. Many stocks in her portfolio have performed exceptionally well this year. Before we get to them, it helps to know what Wood thinks is driving the market. In an October episode of ARK’s “In The Know” series, she spent a good part of the show on AI data centers.
Wood said 90% of all data center financing in the world is in the United States, citing a Bloomberg statistic based on fixed income data. She links that to US tax policy. She expects the money coming into the US to keep pushing the dollar higher.
She also pointed out a risk. The big cloud companies sat on piles of cash for years and never needed to borrow, but they are now selling debt. The price of insuring their debt through credit default swaps has been rising, and she said the neocloud providers are a big part of the reason.
Wood has also made big calls on cloud and AI names before. See whether she was right about Alphabet here.
Methodology
To build this list, we reviewed ARK Investment Management’s December 2025 and September 2026 13F filings. We picked stocks that ARK already owned at the start of 2026 and that were still among its 100 largest holdings at the end of the third quarter. We then ranked 10 of the biggest winners in ascending order of their share-price gains from the start of the year through November 13, 2026. The returns reflect stock-price gains, not ARK’s own investment returns, because the firm changed several positions during the year.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).
You can see the top 5 stocks in this list on our video by clicking the image below:
#10. CareDx, Inc. (NASDAQ:CDNA)
2026 Year-to-Date Return: 285%
CareDx, Inc. (NASDAQ:CDNA) is a precision medicine diagnostics company specializing in transplant monitoring, oncology, and cell therapy. Its testing products help physicians assess transplant recipients for potential organ rejection and monitor patients using molecular diagnostic technologies.
Cathie Wood’s ARK Investment Management held approximately 1.95 million CareDx shares valued at $55.68 million at the end of June 2026. During the third quarter, the fund reduced its stake by approximately 18%, ending September with 1.61 million shares worth $104.59 million.
Piper Sandler recently started coverage of CareDx with an Overweight rating. The brokerage likes the company because it sells tests to transplant patients, and most of those patients are not being tested yet.
Testing reaches only 25% to 35% of kidney transplant patients, 35% to 45% of heart patients, and less than 20% of lung patients, analyst David Westenberg said. He thinks the market underestimates how much CareDx can grow by testing each patient more often, because the patient base is large, long-lived and still underpenetrated, he said.
A growth fund added to its CareDx stake in the second quarter of 2026, and the stock helped the fund’s returns that quarter. Click to read the letter
#9. 10x Genomics, Inc. (NASDAQ:TXG)
2026 Year-to-Date Return: 230%
10x Genomics, Inc. (NASDAQ:TXG) develops instruments, consumables, and software used in biological research. Its technologies enable scientists to analyze individual cells and understand how genes and other biological components interact, supporting research in cancer, immunology, neuroscience, and other fields.
Cathie Wood’s ARK Investment Management held approximately 10 million shares of 10x Genomics valued at $383.52 million at the end of June 2026. During the third quarter, ARK reduced its position by approximately 37%, ending September with 6.27 million shares worth $566.83 million.
Bulls like 10x Genomics for its recurring revenue from consumables that researchers regularly reorder. The company reported a 75% gross margin in the third quarter of 2026, while spatial consumables revenue grew 16%. Its new Atera spatial biology platform has attracted strong initial demand, with management targeting about 50 shipments by year-end. Bulls expect Atera and AI-powered research tools to drive future growth.
However, bears point to sluggish revenue growth of just 1% in the third quarter and continued operating losses. Atera could also replace sales of older products rather than generate entirely new revenue. Competition, uncertain research funding, and the stock’s sharp rally add further risks.
10x Genomics has booked more orders for its new Atera platform than the number of units it plans to ship in all of 2026. See the full bull and bear breakdown
#8. Twist Bioscience Corporation (NASDAQ:TWST)
2026 Year-to-Date Return: 224%
Twist Bioscience Corporation (NASDAQ:TWST) develops synthetic DNA products and technologies used in biotechnology research, drug discovery, and genetic analysis. Its proprietary DNA synthesis platform enables customers to manufacture genetic material for applications ranging from antibody development to next-generation sequencing.
ARK Investment Management held approximately 4.55 million Twist Bioscience shares worth $468.08 million at the end of June 2026. During the third quarter, Wood’s fund reduced its position by approximately 25%, bringing its September holdings to 3.40 million shares valued at $656.64 million.
Twist Bioscience can benefit from growing demand for AI-powered drug discovery and personalized cancer testing. Its AI drug discovery revenue surged 175% to $59.1 million in fiscal 2026, with management targeting $100 million in 2027. Bulls expect repeat orders for DNA, proteins, and testing services to drive long-term growth as biotechnology companies expand their research. The company’s $582 million in liquid resources also provides financial flexibility.
However, bears point to Twist’s steep valuation and continued losses. The stock trades at approximately 12.3 times projected fiscal 2027 sales, compared with the sector median of 3.7 times. Demand for AI drug discovery services may not translate into sustained repeat orders, particularly if drug development programs fail or customers cut research budgets. Slower growth could leave production capacity underused and make the stock’s premium valuation difficult to justify.
Twist Bioscience shares surged on strong results and demand from AI drug discovery, a small-cap fund said in its second-quarter 2026 investor letter. Check the full letter here
#7. Advanced Micro Devices, Inc. (NASDAQ:AMD)
2026 Year-to-Date Return: 125%
Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the world’s leading semiconductor companies, competing with Nvidia in AI accelerators and with Intel in computer and server processors. The company has become an increasingly important supplier of chips used in artificial intelligence infrastructure, cloud computing, and enterprise data centers.
Cathie Wood’s ARK Invest cut its stake in Advanced Micro Devices by 52%, and valuation could be one reason the fund decided to take some profits. AMD trades at 62.4 times forward non-GAAP earnings, more than triple the sector median of 19 times. Its forward enterprise value-to-sales ratio of 15.7 is also roughly five times the sector median, suggesting investors have already priced in substantial AI growth.
However, bulls believe AMD can grow into its valuation as it emerges as a serious competitor to Nvidia. The company’s data center revenue surged 97% in the third quarter of 2026, driven by demand for its EPYC processors and Instinct AI accelerators. AMD has secured major partnerships with OpenAI, Anthropic, Meta, Microsoft, and Alphabet, giving it opportunities to expand its share of the AI chip market. Its growing presence in server CPUs, particularly for agentic AI workloads, provides another advantage. Management expects data center revenue to account for more than 80% of total sales in 2027.
Despite Nvidia’s dominance, AMD could benefit as major cloud providers seek alternative suppliers and expand AI infrastructure spending.
AMD ranks third among Cathie Wood’s five biggest AI and data center stock picks in our earlier coverage, and bulls say it can win by being the strong second option next to Nvidia. Read the full case here
#6. Absci Corporation (NASDAQ:ABSI)
2026 Year-to-Date Return: 107%
Absci Corporation (NASDAQ:ABSI) uses artificial intelligence to develop new antibody-based medicines. Bulls are particularly optimistic about ABS-201, its experimental treatment for pattern hair loss. The company expects to release interim 13-week clinical data in December 2026, followed by full 26-week results in early 2027. Positive results could strengthen the drug’s commercial potential, particularly given its proposed dosing schedule of just two or three injections every six months. Absci is also planning a Phase 2 trial for endometriosis in mid-2027, creating another potential growth opportunity.
ARK Investment Management held approximately 12.93 million Absci shares valued at $149.80 million at the end of June 2026. During the third quarter, Wood’s fund reduced its stake by approximately 8%, bringing its September holdings to 11.93 million shares worth $128.47 million.
Hair-loss drug stocks like Absci are drawing the same Wall Street excitement that Ozempic did, because no new hair-loss drug has won FDA approval since the late 1990s. Click to read why
#5. Cloudflare (NYSE:NET)
2026 Year-to-Date Return: 45%
Bulls like Cloudflare (NYSE:NET) because its Workers platform lets developers run code and AI models on a network of more than 330 data centers, and AI agents are adding a lot of new traffic. Third-quarter revenue grew 39.2% from a year earlier, up from 35.9% growth in the second quarter. More than 10 million developers now use the platform, up from 7.4 million in the previous quarter, and the company added a record number of large customers in a single quarter. Net retention reached 122%, so existing customers keep spending more. Cloudflare also expects its first GAAP profit in the fourth quarter, well ahead of its earlier 2028 target, and its adjusted operating margin hit a record in the third quarter.
Bears point to the price. The stock trades at about 217 times forward earnings, so any slip in growth could hurt. Gross margin fell 2.8 percentage points in the third quarter from a year earlier, because Workers makes up a bigger share of sales. Growth in contracted future revenue slowed to 34% from 38% in the second quarter. Cloudflare still posted a GAAP operating loss in the third quarter. Mark Anderson, who leads its go-to-market team, is set to retire, which adds a leadership change to a sales machine that has worked well.
ARK raised its Cloudflare stake by 221% in the third quarter, and Jim Cramer praised the company’s role in handling AI agent traffic. Click to see the other nine stocks Cathie Wood and Jim Cramer agree on
#4. 908 Devices Inc. (NASDAQ:MASS)
2026 Year-to-Date Return: 80%
908 Devices Inc. (NASDAQ:MASS) develops handheld chemical analysis devices used by government agencies, law enforcement, emergency responders, and industrial customers. Its products employ mass spectrometry and other analytical technologies to identify hazardous substances, illicit drugs, and chemical threats outside traditional laboratories.
ARK Investment Management held approximately 2.03 million shares of 908 Devices worth $17.64 million at the end of the second quarter. During the third quarter, Wood’s fund increased its position by approximately 3%, ending September with 2.09 million shares valued at $25.85 million.
908 Devices entered 2026 with a late-stage sales pipeline twice the size it had at the start of 2025, as fire, law enforcement and defense buyers replace old detection equipment. See what management said on the call
#3. Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
2026 Year-to-Date Return: 75%
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) develops technologies that analyze the adaptive immune system to help diagnose and monitor diseases. Its flagship clonoSEQ diagnostic platform is used to detect measurable residual disease in patients with certain blood cancers, enabling physicians to assess treatment responses and monitor potential relapses.
Cathie Wood’s ARK Investment Management held approximately 2.09 million Adaptive Biotechnologies shares valued at $44.84 million at the end of June 2026. During the third quarter, ARK reduced its shareholding by approximately 8%, bringing its September position to 1.92 million shares worth $55.51 million.
Adaptive’s clonoSEQ test could see more repeat orders because updated multiple myeloma guidelines name clonoSEQ and add more testing points during a patient’s treatment. Read the bull and bear case here
#2. Schrödinger, Inc. (NASDAQ:SDGR)
2026 Year-to-Date Return: 52%
Schrödinger, Inc. (NASDAQ:SDGR) is a computational chemistry and drug discovery company that develops physics-based software to help pharmaceutical companies discover and optimize new medicines. Its technology allows researchers to simulate molecular interactions and assess potential drug candidates before conducting extensive laboratory testing.
Schrödinger could benefit from growing demand for its software, which helps pharmaceutical companies discover new drugs faster and at lower costs. Bulls also like its strategy of helping create biotechnology companies and taking ownership stakes in them. That strategy paid off when Eli Lilly acquired Ajax Therapeutics, a company Schrödinger co-founded, generating approximately $57 million in cash proceeds for Schrödinger. The company could earn more from similar deals in the future. Its growing software contracts and partnerships with major drugmakers provide additional opportunities.
However, bears point to Schrödinger’s slow software growth, continued losses, and setbacks in drug development. The company discontinued one experimental drug following safety concerns and now relies on partners to advance other treatments. Its shift toward cloud-based software has also pressured profit margins. While successful drug discoveries and acquisitions could generate substantial returns, those outcomes are uncertain, and the company may take years to become consistently profitable.
ARK Investment Management held 2.15 million Schrödinger shares valued at approximately $35 million at the end of June 2026. During the third quarter, Wood’s fund increased its position by approximately 10%, bringing its September holdings to 2.37 million shares worth $73.74 million.
Schrödinger is cutting back on costly in-house drug development to focus on its software business, and a Wall Street upgrade to Buy followed that shift. Check what the analysts liked here
#1. Butterfly Network, Inc. (NYSE:BFLY)
2026 Year-to-Date Return: 60.00%
Butterfly Network, Inc. (NYSE:BFLY) develops portable ultrasound devices and cloud-based software designed to make medical imaging more accessible and affordable. Its semiconductor-based Ultrasound-on-Chip technology allows healthcare professionals to perform diagnostic imaging using compact devices rather than traditional ultrasound machines.
Bulls like that its core business is moving toward multiyear software contracts with hospitals. Third-quarter revenue grew 52% from a year earlier, and the company raised its full-year revenue guidance.
Cathie Wood’s ARK Investment Management held 5.09 million Butterfly Network shares worth approximately $42.82 million at the end of the second quarter of 2026. During the third quarter, ARK increased its stake by approximately 3%, ending September with 5.25 million shares valued at $47.08 million.
OpenAI-backed brain-interface startup Merge Labs picked Butterfly as its exclusive ultrasound-on-chip supplier under a multiyear deal, which shows the chip can work in products beyond handheld scanners. Click to read what the deal means for the stock
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.






